A ClinicalTrials.gov post updated yesterday, October 8, shows that terminated a study of CC-90002 in subjects with Acute Myeloid Leukemia, or AML, and high-risk Myelodysplastic Syndrome, or MDS, because “preliminary monotherapy data in relapsed/refractory AML and high-risk MDS did not offer a sufficiently encouraging profile for further dose escalation/expansion.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.